Clinical Trial

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Study acronym: RadVax
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2018-08-23; most recent amendment 2025-08-12.
Status change: Active, Not Recruiting → Recruiting 2020-07-10
Status change: Recruiting → Active, Not Recruiting 2020-03-24
Trial Details
NCT Number NCT03646617
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Melanoma
Enrollment 54 participants
Start Date 2018-11-27
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-13